Showing 2,121 - 2,140 results of 2,687 for search '"chemotherapy"', query time: 0.06s Refine Results
  1. 2121

    Comparison of clinicopathological characteristics and prognosis between primary squamous cell carcinoma of the thyroid and squamous cell carcinoma combined with papillary thyroid c... by Wanyun Yan, Huiying Chen, Xiaoyu Lin, Ruifa Zhou, Feng Zhao, Jiping Su

    Published 2025-01-01
    “…In addition, PSCCT and SCC-PTC also demonstrated similarities in tracheal invasion, esophageal invasion, CK5/6 expression, TG expression, P53 expression, and chemotherapy frequency. The 3-year overall survival rate of PSCCT (19.1%) was lower than that of SCC-PTC (34.6%). …”
    Get full text
    Article
  2. 2122

    Immunological differences between monophasic and biphasic synovial sarcoma with implications for immunotherapy by S. J. Luk, M. E. IJsselsteijn, A. Somarakis, I. Acem, I. Briaire de Bruijn, K. Szuhai, J. V. M. G. Bovee, N. F. C. C. de Miranda, J. H. F. Falkenburg, M. H. M. Heemskerk

    Published 2024-12-01
    “…The immune composition of synovial sarcoma was dominated by CD68+ myeloid cells of which a substantial part was of the CD163+ immunosuppressive phenotype, which increased after chemotherapy or radiotherapy. Biphasic synovial sarcomas were more densely infiltrated by both T cells and myeloid cells than monophasic synovial sarcomas. …”
    Get full text
    Article
  3. 2123

    Metastatic Urothelial Carcinoma from Transplanted Kidney with Complete Response to an Immune Checkpoint Inhibitor by Ryan S. Chiang, Ashton A. Connor, Brant A. Inman, Wen-Chi Foo, David N. Howell, John F. Madden, Matthew J. Ellis, Aparna S. Rege, Michael R. Harrison

    Published 2020-01-01
    “…Approaches to treatment have largely been individualized based on clinical circumstances given the lack of evidence-based guidelines, with therapeutic options ranging from discontinuation of immunosuppression and transplantectomy to the addition of chemotherapy or radiotherapy. Case Presentation. Herein, we describe a 60-year-old woman with metastatic donor-derived upper tract urothelial carcinoma (UTUC) discovered nine years postrenal transplant. …”
    Get full text
    Article
  4. 2124

    Treatment Patterns and Outcomes Among Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States by Robert L. Coleman, Jamie Garside, Jean Hurteau, Joehl Nguyen, Monica Kobayashi

    Published 2023-10-01
    “…**Discussion:** The use of platinum-based chemotherapy for first-line treatment of advanced or recurrent EC predominates in the real-world setting, despite the poor long-term survival outcomes associated with most of these regimens. …”
    Get full text
    Article
  5. 2125
  6. 2126

    Case report: Transarterial chemoembolization for nasal hemangiosarcoma in a dog by Keunho Kim, Changgyu Lim, Songyi Kim, Hearang Lim, Sang-Hwan Hyun, Byeong-Teck Kang, Dongwoo Chang, Namsoon Lee

    Published 2025-01-01
    “…Although initial treatments with radiotherapy and chemotherapy provided temporary relief, the symptoms reappeared 11 months later. …”
    Get full text
    Article
  7. 2127

    Malignant melanoma of the ear - a literature review of a rare otological tumor by Nicol Dardzińska, Marta Dziedziak, Aleksandra Grzegorczyk, Natalia Hopej, Justyna Korus

    Published 2025-01-01
    “…However it is suggested to choose the surgical approach that can be combined with both radiotherapy and chemotherapy. The prognosis remains poor despite the significant development of medicine. …”
    Get full text
    Article
  8. 2128

    Determinants of Demoralization Syndrome and Social Support Among Patients with Breast Cancer: A Cross-Sectional Study by Yang L, Song LX, Zhang L, Yang Y, Zhang YM

    Published 2025-01-01
    “…Among patients with BC, demographic variables such as age, education level, residential address, monthly income, occupation, and receipt of chemotherapy were the main influencing factors (P < 0.05), whereas factors such as current status of children, and surgical methods were not the main influencing factors (P < 0.05). …”
    Get full text
    Article
  9. 2129

    TIM‐4 increases the proportion of CD4+CD25+FOXP3+ regulatory T cells in the pancreatic ductal adenocarcinoma microenvironment by inhibiting IL‐6 secretion by Ziyao Wang, Zerong Xie, Yu Mou, Ruiman Geng, Chen Chen, Nengwen Ke

    Published 2024-09-01
    “…Conclusion TIM‐4 has the potential to be an immunotherapeutic target or to improve the efficacy of chemotherapy for PDAC.…”
    Get full text
    Article
  10. 2130
  11. 2131

    Recent advances in bacterial outer membrane vesicles: Effects on the immune system, mechanisms and their usage for tumor treatment by Shuo Xiang, Qiufang Yao, Arshad Khan, Dong Wang

    Published 2024-12-01
    “…This dual capability enhances the effectiveness of immunotherapy combined with chemotherapy or phototherapy, thereby improving anticancer drug efficacy. …”
    Get full text
    Article
  12. 2132

    Therapeutic Targeting of Fibroblast Growth Factor Receptors in Gastric Cancer by Mikito Inokuchi, Yoshitaka Fujimori, Sho Otsuki, Yuya Sato, Masatoshi Nakagawa, Kazuyuki Kojima

    Published 2015-01-01
    “…Chemotherapy has become the global standard treatment for patients with metastatic or unresectable gastric cancer (GC), although outcomes remain unfavorable. …”
    Get full text
    Article
  13. 2133

    Adjuvant Radiotherapy for Synchronous Bilateral Testicular Seminoma: A Case Report and a Review of the Pertinent Literature by Daniel A. Jones, Elizabeth C. Ester, David Leavitt, Robert Sweet, Badrinath Konety, Gautam Jha, L. Chinsoo Cho

    Published 2013-01-01
    “…Organ preservation remains investigational. Chemotherapy is probably a reasonable option. We propose that patients with bilateral stage I synchronous GCT, with concordant seminoma histology, should be managed with bilateral orchiectomy, followed by paraaortic radiotherapy.…”
    Get full text
    Article
  14. 2134

    Trace elements‐based Auroshell gold@hematite nanostructure: Green synthesis and their hyperthermia therapy by Hadil M. Alahdal, Sumya Ayad Abdullrezzaq, Hawraz Ibrahim M. Amin, Sitah F. Alanazi, Abduladheem Turki Jalil, Mehrdad Khatami, Marwan Mahmood Saleh

    Published 2023-02-01
    “…Abstract Hyperthermia is an additional treatment method to radiation therapy/chemotherapy, which increases the survival rate of patients without side effects. …”
    Get full text
    Article
  15. 2135

    Development and verification of prognostic nomogram for extraskeletal Ewing's sarcoma based on the SEER database by Feipeng Xiao, Weizhen Wang

    Published 2025-01-01
    “…Conclusion: Stage, age, tumour size, chemotherapy, and surgery may be independent prognostic factors for EES. our study produced a survival nomogram that can be used to predict the prognosis of patients with EES and validated its performance, which may help clinicians evaluate the condition of patients with EES and choose personalised treatment.…”
    Get full text
    Article
  16. 2136

    BRAF inhibitor monotherapy in BRAFV600E-mutated pediatric low-grade glioma: a single center’s experience by S. S. McThenia, S. S. McThenia, S. S. McThenia, K. M. Reddy, K. M. Reddy, E. Damaraju, E. Castellino, Z. He, R. Beer, F. Chien, F. Chien, F. Chien, R. C. Castellino, R. C. Castellino, R. C. Castellino, A. E. Goldman-Yassen, A. E. Goldman-Yassen, J. R. Fangusaro, J. R. Fangusaro, J. R. Fangusaro, T. MacDonald, T. MacDonald, T. MacDonald

    Published 2025-01-01
    “…BackgroundPediatric low-grade gliomas (pLGGs) have an overall survival of over 90%; however, patients harboring a BRAFV600E alteration may have worse outcomes, particularly when treated with classic chemotherapy. Combined BRAF/MEK inhibition following incomplete resection demonstrated improved outcome in BRAFV600E altered pLGG compared to combined carboplatin/vincristine chemotherapy and is now considered the standard FDA-approved treatment for this group of tumors. …”
    Get full text
    Article
  17. 2137

    Pharmacological ascorbate combined with rucosopasem selectively radio-chemo-sensitizes NSCLC via generation of H2O2 by C.F. Pulliam, M.A. Fath, S. Sho, S.T. Johnson, B.A. Wagner, M. Singhania, A.L. Kalen, K. Bayanbold, S.R. Solst, B.G. Allen, B.N. George, J.M. Caster, G.R. Buettner, D.P. Riley, J.L. Keene, R.A. Beardsley, D.R. Spitz

    Published 2025-03-01
    “…Most importantly, the combination of RUC + P-AscH‾ was found to sensitize both H1299T and A549 cell types to radio-chemotherapy with cisplatin (CIS) + etoposide (ETOP). …”
    Get full text
    Article
  18. 2138

    Prophylactic Sublay Mesh Placement During Stoma Closure to Prevent Incisional Hernias: a Pilot Study by Yana Belenkaya, Sergey Gordeev, Nikolay Matveyev, Zaman Mamedli

    Published 2024-12-01
    “…The exclusion criteria included patients with synchronous and metachronous cancers, human immunodeficiency virus, an Eastern Cooperative Oncology Group score of >2, and those undergoing chemotherapy. The sublay mesh placement technique was used, with the endpoints being surgical site infection rate at 30 days, operative time, mesh placement time, and postoperative morbidity (Clavien-Dindo classification). …”
    Get full text
    Article
  19. 2139

    Therapy-induced senescent cancer cells contribute to cancer progression by promoting ribophorin 1-dependent PD-L1 upregulation by Hyun Jung Hwang, Donghee Kang, Jisoo Shin, Jonghun Jung, Soyeon Ko, Kyung Hee Jung, Soon-Sun Hong, Ji Eun Park, Myung Jin Oh, Hyun Joo An, Wen-Hao Yang, Young-Gyu Ko, Jong-Ho Cha, Jae-Seon Lee

    Published 2025-01-01
    “…Abstract Conventional chemotherapy- and radiotherapy-induced cancer senescence, which is characterized by poor proliferation, drug resistance, and senescence-associated secretory phenotype, has gained attention as contributing to cancer relapse and the development of an immunosuppressive tumor microenvironment. …”
    Get full text
    Article
  20. 2140

    Recent progress on anti-cancer activity of thiadiazoles: A review by C.R. Santhosh, Sampath Chinnam, Nagaraju Kottam, S Amreen, Guddekoppa S. Ananthnag, G.M. Madhu, Samata Gadde, Viola Tressa Fernandes, Haritha Arnipalli

    Published 2025-01-01
    “…Thiadiazoles exhibit beneficial synergistic effects when used with other anticancer treatments like chemotherapy or targeted therapy. They have shown considerable anti-cancer action against various cancer cell lines. …”
    Get full text
    Article